Home  |  Top News  |  Most Popular  |  Video  |  Multimedia  |  News Feeds  |  Feedback
  Medicine  |  Nature & Earth  |  Biology  |  Technology & Engineering  |  Space & Planetary  |  Psychology  |  Physics & Chemistry  |  Economics  |  Archaeology
Top > Medicine, Health Care > Combination Overcomes Breast Cancer Resistance… >

Combination Overcomes Breast Cancer Resistance to Herceptin

Published: March 14, 2011.
Released by University of Texas M. D. Anderson Cancer Center  

HOUSTON - Breast cancer tumors take numerous paths to resist the targeted drug Herceptin, but a single roadblock at a crucial crossroads may restore a tumor's vulnerability to treatment, scientists at The University of Texas MD Anderson Cancer Center report on line at Nature Medicine.

Adding the drug saracatinib to Herceptin treatment shrinks previously resistant tumors by cutting off at least five different molecular pathways, each of which can resist, said senior author Dihua Yu, M.D., Ph.D., professor in MD Anderson's Department of Molecular and Cellular Oncology.

"Scientists have identified so many ways by which a tumor resists Herceptin that it raises an important issue for treatment," Yu said. "Will we have to give patients six drugs or 10 drugs to block them all? The side effects would be awful. Two pills are better. This combination is a promising therapy for those with Herceptin-resistant breast cancer."

Working in cell lines, mouse models of breast cancer and checking their work in human tumor samples, Yu and colleagues identified SRC, a known cancer-promoting protein, as the crucial common downstream component of multiple resistance pathways.

Saracatinib is an SRC inhibitor, thwarting that protein and allowing Herceptin to work again in tumors that have a high amount of the HER2 protein.

Only about 26 percent of women with HER2-positive breast cancer respond to Herceptin as single therapy. Between 40 and 60 percent respond to the drug when combined with other chemotherapy.

Combination is ready for clinical trials

Yu said saracatinib has been tested in phase I and phase II clinical trials as a single treatment against late-stage cancers. It has a favorable side effects profile.

"It didn't work as a single agent, but very few drugs work by themselves against late stage disease," Yu said. "Our experiments confirmed its lack of efficacy as a sole treatment. But combined with Herceptin, it's beautiful."

Another SRC inhibitor, dasatinib, has been approved by the U.S. Food and Drug Administration as an anti-cancer drug, but it has harsher side effects, said Siyuan Zhang, Ph.D., a postdoctoral fellow in Yu's lab and the paper's first author.

A tumor-suppressor's job

In 2004, Yu's lab discovered that loss of the tumor-suppressing gene known as PTEN led to Herceptin-resistant tumors. PTEN is a phosphotase - a protein whose function is to strip phosphate chemical groups off of other molecules.

PTEN has two components, one to remove phosphate groups from lipids, and another to remove them from proteins. PTEN's target protein however, was unknown.

Zhang discovered that SRC is a PTEN target. With its phosphate groups, SRC is active. PTEN stifles SRC by peeling away the phosphates.

If PTEN loss leads to Herceptin resistance, and PTEN targets SRC, would that make SRC the culprit?

On the trail of SRC

In a series of experiments the researchers found:

  • SRC is active in breast cancer cells once vulnerable but now resistant to Herceptin and in cells that are resistant from the start.
  • Activation of SRC drives resistance to Herceptin. Tumors with low SRC levels treated by Herceptin shrunk to 20 percent of their original volume in 21 days while SRC-heavy tumors increased by nearly 400 percent over the same time in mouse experiments.
  • SRC activity correlates with patient response to Herceptin. Assessing SRC activation in samples of 57 human breast cancer tumors, the team found that more than 90 percent of tumors with low SRC responded compared with 40 percent of tumors with active SRC.
  • Patients with little active SRC had a median survival of 57.9 months compared with 34.2 months in those with high SRC activity.
  • SRC is activated by a number of receptor tyrosine kinases that cause resistance, including IGF-1R, EGFR, ERBB2, HER3, and Met, separate pathways that work through SRC. "Block SRC, and you reverse them all," Zhang said.


Crushing resistance

Combining Herceptin and saracatinib to treat resistant tumors in mice reduced tumor volume by 90 percent in 25 days. Herceptin alone kept tumor volume about the same during the same period, while control and saracatinib alone permitted growth of more than 200 percent.

The difference was more striking in tumors deficient in SRC's enemy, the PTEN tumor-suppressor. The combination reduced tumor volume by more than 90 percent while the two drugs alone allowed growth of between 200 and 400 percent.

This study was funded by grants from the National Cancer Institute, MD Anderson Breast Specialized Program of Research Excellence; Department of Defense Center of Excellence; Susan G. Komen Breast Cancer Foundation Promise Grant; the Cancer Prevention and Research Institute of Texas, the MD Anderson Breast SPORE Career Development Award and Susan G. Komen Breast Cancer Foundation Postdoctoral Fellowship.




The above story is based on materials provided by University of Texas M. D. Anderson Cancer Center.

Translate this page: Chinese French German Italian Japanese Korean Portuguese Russian Spanish


comments powered by Disqus


Related »

Breast 
4/14/10 
★★★ 
Decoding Tumor Genomes Reveals Clues to Spread of Deadly Breast Cancer
Using powerful DNA sequencing technology to decode the genomes of cancer patients, scientists at Washington University School of Medicine …
Cells 
8/15/11 
Human Breast Tumor Evasion of the Antitumor Immune Response
The main cause of death in women with breast cancer is spread of the original tumor to distant sites, …
Tumor 
1/30/12 
4-week Vaccination Regimen Knocks Out Early Breast Cancer Tumors, Penn Researchers Report
Researchers at the Perelman School of Medicine at the University of Pennsylvania report that a short course of vaccination …
Treatment 
11/10/11 
New Target Identified to Stop the Spread of Breast Cancer
A new potential target to slow breast cancer tumor progression and metastasis has been identified by a team of …
Cancer 
8/6/12 
Heterogeneous ER+ Breast Cancer Models Allow More Accurate Drug Testing
Cell cultures are homogeneous. Human tumors are not. A University of Colorado Cancer Center study recently published in the …
Breast 
10/24/11 
★★ 
Will My Breast Cancer Spread? Discovery May Predict Probability of Metastasis
Researchers from Huntsman Cancer Institute (HCI) at the University of Utah have discovered a new way to model human …
Breast 
2/22/12 
Researchers Reveal How Cancer Cells Change Once They Spread to Distant Organs
Oncologists have known that in order for cancer cells to spread, they must transform themselves so they can detach …
Tumor 
3/30/11 
Interventional Radiologists Provide Hope in Delaying Growth, Spread of Breast Cancer
CHICAGO, Ill. (March 29, 2011)—The growth and spread of breast cancer tumors may be delayed with a promising treatment …
Cancer 
5/17/11 
★★★ 
VCU Massey Cancer Center Finds New Biomarker That Predicts Breast Cancer Relapse
Richmond, Va. (May 16, 2011) – Researchers from Virginia Commonwealth University Massey Cancer Center have discovered a new biomarker …
Cancer 
3/12/10 
'Microtentacles' on Tumor Cells Appear to Play Role in How Breast Cancer Spreads
Researchers at the University of Maryland Marlene and Stewart Greenebaum Cancer Center have discovered that "microtentacles," or extensions of …
Tumor 
5/19/11 
Recurring Cancers in Women with a History of Breast Cancer Differ from the Original Tumors
CHICAGO, IL (May 18, 2011)––When women with a history of breast cancer learn they have breast cancer again, one …
Tumors 
7/10/14 
Fox Chase Researchers Recommend Updating the Staging Criteria for Breast Cancer Diagnoses
New findings from Fox Chase Cancer Center paint a relatively optimistic picture of women's chances of surviving a subset …
More » 
 
© Newsline Group  |  About  |  Privacy Policy  |  Feedback  |  Mobile